Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer With HRR Mutation and MSS

Condition:   Gastric Cancer Stage IV Intervention:   Drug: olaparib+pembrolizumab+paclitaxel Sponsor:   Yonsei University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials